Dr. Garcia-Manero on Rigosertib in Patients with High-Risk MDS After Failure of Hypomethylating Agents

Guillermo Garcia-Manero, MD
Published: Thursday, Apr 30, 2015



Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with myelodysplastic syndromes (MDS) who have failed hypomethylating agents.

Garcia-Manero says this agent isn’t a specific selective kinase inhibitor. This is important because the data that has started to emerge for studies of hypomethlating failure biology implicates kinase deregulation in this context. Garcia-Manero says it makes sense that an inhibitor of kinase may have a role in this space.

Data has been published that has found that at the time of failure, a subset of patient acquire mutations from FLT3 and RAS and other data has found that MAP-kinase pathway is activated in these patients, Garcia-Manero says.

Garcia-Manero says a clinical trial is being prepared that will consist of biomarkers looking at the patients that are responding, or not responding, to rigosertib and will help researchers better understand kinase deregulation in this group of patients.

<<< View more from the 2015 MDS Symposium



Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with myelodysplastic syndromes (MDS) who have failed hypomethylating agents.

Garcia-Manero says this agent isn’t a specific selective kinase inhibitor. This is important because the data that has started to emerge for studies of hypomethlating failure biology implicates kinase deregulation in this context. Garcia-Manero says it makes sense that an inhibitor of kinase may have a role in this space.

Data has been published that has found that at the time of failure, a subset of patient acquire mutations from FLT3 and RAS and other data has found that MAP-kinase pathway is activated in these patients, Garcia-Manero says.

Garcia-Manero says a clinical trial is being prepared that will consist of biomarkers looking at the patients that are responding, or not responding, to rigosertib and will help researchers better understand kinase deregulation in this group of patients.

<<< View more from the 2015 MDS Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x